← Genmab A/S (GMAB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Genmab A/S (GMAB)
Pharmaceutical Preparations · market cap $21.4B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05
Earnings
Pipeline
14
programs
Upcoming events
5
next 90d+
Dossier
Ready
cached
Genmab A/S (GMAB) is a Danish antibody-focused biotech trading at ~$29.54 with a market cap of ~$15.7B, operating across oncology indications through a broad pipeline that spans multiple Phase 2 and Phase 3 programs. The company's most clinically advanced proprietary asset is epcoritamab, a bispecific antibody in Phase 3 for diffuse large B-cell lymphoma (DLBCL), with a cluster of high-importance readouts expected through mid-2027. A mixed Phase 3 result was reported in June 2026, introducing uncertainty into the near-term catalyst stack.
The catalyst path
- 2026-11-05Earningsimp 5/10
- 2027-03-15 (est.)Phase 2 · Epcoritamabimp 7/10
- 2027-03-15 (est.)Phase 3 · Epcoritamabimp 9/10
- 2027-09-15 (est.)Phase 2 · Epcoritamab (monotherapy)imp 7/10
- 2027-09-30 (est.)Phase 2 · gemcitabine and oxaliplatinimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| gemcitabine and oxaliplatin | Phase 2 | Diffuse Large B-Cell Lymphoma |
| GEN1042 | Phase 2 | Malignant Solid Tumor |
| tisotumab vedotin | Phase 2 | Solid Tumor |
| Zalutumumab | Phase 3 | Head and Neck Cancer |
| Epcoritamab | Phase 3 | Diffuse Large B-Cell Lymphoma |
| Epcoritamab (monotherapy) | Phase 2 | Diffuse Large B Cell Lymphoma |
| Rina-S | Phase 3 | Endometrial Cancer |
| GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells. | Phase 2 | Breast Cancer, Breast Neoplasms |
| Enapotamab vedotin (HuMax-AXL-ADC) | Phase 2 | Ovarian Cancer |
| Investigator's Choice Chemotherapy | Phase 3 | Diffuse Large B-Cell Lymphoma |
| Acasunlimab | Phase 3 | Cutaneous Melanoma |
| GEN1286 | Phase 2 | Advanced Solid Tumor |
| Acasunlimab in combination with docetaxel (in a single expansion cohort) | Phase 2 | Solid Tumors |
| HuMax-CD4 | Phase 2 | Cutaneous T-Cell Lymphoma |
Price & technical context
3-month
+21.2%
6-month
+26.9%
12-month
+8.8%
52-wk range
$23.85–$35.67
vs 50-day MA
+6.1%
vs 200-day MA
+16.7%
Realized vol
37.4%
Max drawdown
-32.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GMAB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 14 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.